Repotrectinib Shows Promise in Clinical Trials

Share on twitter
Share on linkedin
Share on facebook
Share on reddit
Share on pinterest

Cancer is a deadly disorder that has little to no cure at all. Even after undergoing multiple surgeries and chemotherapies, people still succumb to the pain of cancer. But what if we told you those days are about to be gone? Science is on its way to making another breakthrough in its journey to fight cancer.

As per medical reports in 2020, the majority of cancer-related issues arose due to lung cancer. That too from a specific type of cancer known as non-small cell lung cancer (NSCLC). This type of cancer occurs when the cells in the lungs come together and cause a tumor-type mass. This tumor could be cancerous or non-cancerous. Either way, chemotherapy, radiation therapy, and surgical treatments are required to get rid of this.

There have not been any medications as powerful and as effective. However, it’s time to get introduced to Repotrectinib. Repotrectinib is a new drug still undergoing tests and screenings that focus on reducing or completely eliminating the elements that cause the growth of these cancerous cells.

Other Treatments for NSCLC

Nowadays, we have medications such as Avastin and Cyramza given along with chemotherapy to treat NSCLC. The primary threat to any cancer patient is the development of new blood vessels that are cancerous. The best way to prevent the spread of cancer is to restrict the growth of blood vessels around the cancerous cells. Both these drugs work toward the same cause and prevent the formation of new cancerous blood vessels.

However, these treatments usually have certain side effects due to their high power and dosage. These side effects could include high blood pressure, fatigue, and decreased WBCs, and in turn increase in risks of infections, headaches, and increased internal body heat, which might result in skin issues and mouth sores, loss of appetite, diarrhea, drowsiness, etc.

Repotrectinib for NSCLC

Repotrectinib is particularly powerful for ROS1-positive NSCLC cases. Such cases occur due to the fusion of ROS genes with a part of another gene that causes its mutation into a cancerous growth. It is also an effective treatment for NSCLC generated due to the fusion of NTRK genes.

The drug reaches the inherent ATP Pockets and minimizes any steric interference even when mutations are present. FDA has already granted 2 BTDs (Breakthrough Therapy Designation) to Repotrectinib. Multiple tests and trials have been done on various groups of patients. Both these forms of NSCLC are quite widely spread and have no satisfactory treatments available for them. Repotrectinib has taken it a step forward.

Final Words

Even though this medication is not largely available for sale (as many tests are still pending), it is an asset to the country.

With scientific advancements, we a step closer to saving human lives every day. Back in the day, there used to be no concrete solution to cancer. However, with scientists working day and night and showing results such as Repotrectinib, we are certainly on the path toward a bright future.

Related Post